Coby Health review

Coby Health gives comparison shoppers more useful dose-level pricing than many competitors, but its starting price is a poor estimate of maintenance spending. Monthly compounded semaglutide starts at $159 for the first 0.25 mg month and reaches $249 at the listed higher doses. Tirzepatide starts at $239 and reaches $439. Bundles can lower the monthly equivalent, but require larger payments and can ship several months at once. The medical consultation, prescription, medication and shipping are included, without a separate membership charge. Its terms identify Beluga Health, P.A. as a medical group, a useful distinction from Coby itself, which is a technology platform. The trade-off is a tight cancellation window: once a prescription is sent to the pharmacy, Coby says the order cannot be changed. It is a reasonable comparison for patients who can match their next prescribed dose to a published plan, rather than choosing from the cheapest headline.

Coby Health connects patients with independent medical and pharmacy services through an online platform. The company explicitly says that it does not itself provide medicine or operate the dispensing service, and that payment does not guarantee a prescription. Its terms name Beluga Health, P.A. among the medical groups providing care, while allowing prescriptions to be filled or transferred among contracted pharmacies. The reviewed pages did not supply a single named pharmacy guaranteed for every GLP-1 order. Weight management is the main public offering, with compounded semaglutide and tirzepatide; NAD+ injections and sermorelin are also listed. Its homepage excludes Arkansas, Louisiana, Mississippi and New Mexico from the GLP-1 program, so city pages for places such as Chicago or Los Angeles should not be read as a substitute for the actual state eligibility check. Coby presents the service as self-pay and says patients do not need insurance.

The patient begins with an online health questionnaire that Coby estimates takes about three minutes. A medical professional reviews the information and determines whether a prescription is appropriate. The GLP-1 pages include the initial consultation, prescription, medication, shipping and an injection kit with syringes and alcohol pads in the plan description. Coby advertises continuing access to medical support and monthly or multimonth ordering options. Its homepage says no subscription is required, yet also describes monthly subscriptions that can be canceled; the sensible interpretation is that a patient must check the selected order’s actual renewal terms rather than assuming every purchase is one-time. A clinician must determine the next dose before a patient picks a same-dose or titration bundle. If several months arrive together, the patient should also obtain the pharmacy’s written storage conditions, beyond-use dates and instructions for what happens if treatment changes before the supply is used. Those details are particularly important when a bundle contains future dose steps.

The monthly semaglutide table shows $159 for month one at 0.25 mg, $199 at 0.5 mg, $229 at 1 mg and $249 at 1.7 or 2.4 mg. The introductory twelve-week bundle is $399 upfront for the stated 0.25-to-1 mg progression. Longer same-dose bundles and continuation titration bundles have their own prices; they should not be compared as if every patient qualifies for the lowest equivalent. The tirzepatide monthly table shows $239 at 2.5 mg, $299 at 5 mg, $329 at 7.5 mg, $379 at 10 mg and $439 at 12.5 or 15 mg. Its first-quarter bundle is $697, with all three months shipped together, while the first six months are listed at $1,590 shipped in two three-month supplies. Those are upfront package amounts, not ordinary monthly installments. NAD+ is advertised at $239 on a monthly plan and $597 for three months, although the page describes the monthly supply as every four weeks. The sermorelin page carries different headline and lower-page monthly numbers, so request an itemized quote instead of extending a GLP-1 price assumption to longevity care. Coby says a successful cancellation before pharmacy ordering still loses a $50 visit and clinical fee; attempts to cancel are not guaranteed, and shipped orders cannot be refunded.

Coby’s GLP-1 products are compounded semaglutide and compounded tirzepatide injections. The official pages explicitly distinguish them from Ozempic, Wegovy, Mounjaro and Zepbound and state that they are not reviewed or approved by the FDA for safety or effectiveness. That distinction is a positive disclosure, but it does not establish clinical equivalence, manufacturing quality for a particular lot, or that a compounded medicine is appropriate for a particular patient. The prescriber should explain why an approved finished product cannot meet the patient’s medical needs. The NAD+ and sermorelin pages broaden the menu but include incomplete placeholder FAQ text, which limits their usefulness for deciding who should receive those therapies or what follow-up is provided. Someone interested mainly in longevity care should ask for the exact formulation, dose, pharmacy and monitoring plan before purchasing, rather than relying on a general wellness promise or on the comparatively detailed GLP-1 pricing tables.